T1	PROC 46 68	Ensayo clínico fase II
#1	AnnotatorNotes T1	C0282460; Phase 2 Clinical Trials; Research Activity
T2	PROC 74 93	evaluar la eficacia
#2	AnnotatorNotes T2	C1707887; Efficacy Study; Research Activity
T3	PROC 108 119	tratamiento
#3	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	DISO 137 158	neumonía por COVID-19
T5	PROC 181 253	Estudio prospectivo, fase II, aleatorizado, abierto, de grupos paralelos
T6	PROC 259 278	evaluar la eficacia
#4	AnnotatorNotes T6	C1707887; Efficacy Study; Research Activity
T7	CHEM 282 299	hidroxicloroquina
#5	AnnotatorNotes T7	C0020336; hydroxychloroquine; Organic Chemical · Pharmacologic Substance
T8	CHEM 321 329	imatinib
#6	AnnotatorNotes T8	C0935989; imatinib; Organic Chemical · Pharmacologic Substance
T9	DISO 376 398	neumonía por SARS Cov2
T10	DISO 400 408	COVID-19
#7	AnnotatorNotes T10	C5203670; COVID19 (disease); Disease or Syndrome
T11	DISO 437 458	Neumonía por COVID-19
T12	DISO 485 507	Neumonía por SARS Cov2
T13	DISO 509 517	COVID-19
#8	AnnotatorNotes T13	C5203670; COVID19 (disease); Disease or Syndrome
T14	PROC 610 621	Diagnostico
#9	AnnotatorNotes T14	C0011900; Diagnosis; Diagnostic Procedure
T15	PROC 559 583	consentimiento informado
#10	AnnotatorNotes T15	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T16	DISO 633 649	Neumonía COVID19
T17	DISO 722 730	síntomas
#11	AnnotatorNotes T17	C1457887; Symptoms; Sign or Symptom
T18	CHEM 760 770	medicación
#12	AnnotatorNotes T18	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T19	PROC 776 779	ECG
#13	AnnotatorNotes T19	C1623258; Electrocardiography; Diagnostic Procedure
T20	ANAT 803 811	hepática
#14	AnnotatorNotes T20	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T21	ANAT 813 818	renal
#15	AnnotatorNotes T21	C0022646; Kidney; Body Part, Organ, or Organ Component | C1278978; Entire kidney; Body Part, Organ, or Organ Component
T22	CHEM 892 900	fármacos
#16	AnnotatorNotes T22	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T23	ANAT 926 938	granulocitos
#17	AnnotatorNotes T23	C0018183; granulocyte; Cell
T24	ANAT 974 983	plaquetas
#18	AnnotatorNotes T24	C0005821; Blood Platelets; Cell
T25	CHEM 308 319	baricitinib
#19	AnnotatorNotes T25	C4044947; baricitinib; Organic Chemical · Pharmacologic Substance
T26	CHEM 332 341	lopinavir
#20	AnnotatorNotes T26	C0674432; lopinavir; Organic Chemical · Pharmacologic Substance
T27	CHEM 342 351	ritonavir
#21	AnnotatorNotes T27	C0292818; ritonavir; Organic Chemical · Pharmacologic Substance
T28	DISO 1153 1158	COVID
T29	PROC 1088 1091	ALT
#22	AnnotatorNotes T29	C0201836; Alanine aminotransferase measurement; Laboratory Procedure
T30	DISO 1166 1174	neumonía
#23	AnnotatorNotes T30	C0032285; Pneumonia; Disease or Syndrome
T31	PROC 1180 1191	Tratamiento
#24	AnnotatorNotes T31	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T32	CHEM 1217 1234	drogas de estudio
#25	AnnotatorNotes T32	C0013230; Investigational New Drugs; Pharmacologic Substance
T33	DISO 1239 1269	Afectación médica concomitante
T34	DISO 1280 1283	ICC
#26	AnnotatorNotes T34	C0018802; Congestive heart failure; Disease or Syndrome
T35	DISO 1287 1290	IAM
#27	AnnotatorNotes T35	C0027051; Myocardial infarction; Disease or Syndrome | C0155626; Acute myocardial infarction; Disease or Syndrome
T36	DISO 1310 1326	Angina inestable
#28	AnnotatorNotes T36	C0002965; Angina, Unstable; Disease or Syndrome
T37	DISO 1330 1344	Miocardiopatía
#29	AnnotatorNotes T37	C0878544; Cardiomyopathies; Disease or Syndrome
T38	DISO 1348 1368	Arritmia ventricular
#30	AnnotatorNotes T38	C0085612; Ventricular arrhythmia; Disease or Syndrome
T39	DISO 1382 1385	HTA
#31	AnnotatorNotes T39	C0020538; Hypertensive disease; Disease or Syndrome
T40	DISO 1403 1424	Trastornos psicóticos
#32	AnnotatorNotes T40	C0033975; Psychotic Disorders; Mental or Behavioral Dysfunction
T41	DISO 1443 1454	Infecciones
#33	AnnotatorNotes T41	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T42	DISO 1482 1491	Hepatitis
#34	AnnotatorNotes T42	C0019158; Hepatitis; Disease or Syndrome
T43	DISO 1504 1513	Neoplasia
#35	AnnotatorNotes T43	C0006826; Malignant Neoplasms; Neoplastic Process | C0027651; Neoplasms; Neoplastic Process | C1882062; Neoplastic disease; Neoplastic Process
T44	PROC 1517 1539	tratamiento oncológico
#36	AnnotatorNotes T44	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T45	CHEM 1573 1583	medicación
#37	AnnotatorNotes T45	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T46	DISO 1591 1615	síndrome de malabsorción
#38	AnnotatorNotes T46	C0024523; Malabsorption Syndrome; Disease or Syndrome
T47	PROC 1034 1046	aclaramiento
T48	PROC 1662 1691	procedimientos de seguimiento
T49	CHEM 1827 1848	medicación de estudio
#39	AnnotatorNotes T49	C0013230; Investigational New Drugs; Pharmacologic Substance
T50	PROC 905 938	Recuento absoluto de granulocitos
T51	PROC 1001 1003	Hb
#40	AnnotatorNotes T51	C0518015; Hemoglobin measurement; Laboratory Procedure
T52	PROC 1017 1019	Cr
#41	AnnotatorNotes T52	C0201975; Creatinine measurement; Laboratory Procedure
T53	PROC 1061 1072	Bilirrubina
#42	AnnotatorNotes T53	C0863174; Blood bilirubin measurement; Laboratory Procedure
T54	PROC 1084 1087	AST
#43	AnnotatorNotes T54	C0201899; Aspartate aminotransferase measurement; Laboratory Procedure
T55	PROC 956 983	Recuento absoluto plaquetas
T56	ANAT 1357 1368	ventricular
#44	AnnotatorNotes T56	C0018827; Heart Ventricle; Body Part, Organ, or Organ Component | C1280934; Entire cardiac ventricle; Body Part, Organ, or Organ Component
T57	DISO 1473 1476	VIH
#45	AnnotatorNotes T57	C0458074; Human immunodeficiency virus (HIV) status; Finding
T58	DISO 1713 1753	episodios tromboembólicos o hemorrágicos
T59	Date 13 17	2020
T60	LIVB 123 132	pacientes
#46	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	LIVB 362 371	pacientes
#47	AnnotatorNotes T61	C0030705; Patients; Patient or Disabled Group
T62	Age 596 604	≥18 años
T65	Duration 686 701	Menos de 7 días
T72	Neg_cue 1137 1139	No
T73	Neg_cue 1163 1165	No
T75	Duration 1291 1306	6 meses previos
T79	Neg_cue 1550 1566	Incapacidad para
T80	Route 1584 1588	oral
#48	AnnotatorNotes T80	C1527415; Oral Route of Drug administration; Functional Concept
T82	Neg_cue 1620 1636	Incapacidad para
T83	Duration 1781 1796	últimos 6 meses
T84	LIVB 1853 1872	Mujeres embarazadas
#49	AnnotatorNotes T84	C0033011; Pregnant Women; Population Group
T85	LIVB 498 507	SARS Cov2
#50	AnnotatorNotes T85	C5203676; SARS-CoV-2; Virus
T86	LIVB 389 398	SARS Cov2
#51	AnnotatorNotes T86	C5203676; SARS-CoV-2; Virus
T63	PHYS 795 833	Función hepática, renal y hematológica
#52	AnnotatorNotes T63	C0232741; Liver function; Organ or Tissue Function + C0232804; Renal function; Organ or Tissue Function + C0221130; Hematologic function; Organ or Tissue Function
T64	PHYS 1861 1872	embarazadas
#53	AnnotatorNotes T64	C0032961; Pregnancy; Organism Function
T66	PROC 655 671	Estado funcional
#54	AnnotatorNotes T66	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
A1	Assertion T28 Negated
A2	Assertion T30 Negated
A3	Assertion T45 Negated
A4	Assertion T80 Negated
A5	Assertion T48 Negated
A6	Assertion T49 Contraindicated
A7	Status T58 History_of
A8	Status T31 History_of
A9	Status T32 History_of
A10	Status T35 History_of
#55	AnnotatorNotes T4	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#56	AnnotatorNotes T9	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#57	AnnotatorNotes T11	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#58	AnnotatorNotes T12	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#59	AnnotatorNotes T16	C5419163; COVID-19-Associated Pneumonia; Disease or Syndrome 
#60	AnnotatorNotes T28	C5203670; COVID19 (disease); Disease or Syndrome
#61	AnnotatorNotes T5	C0033522; Prospective Studies; Research Activity + C0282460; Phase 2 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity + C1709323; Open Label Study; Research Activity + C2826345; Parallel Study; Research Activity
#62	AnnotatorNotes T47	C0373595; Creatinine clearance measurement; Laboratory Procedure
T67	Neg_cue 1425 1427	no
T68	Quantifier_or_Qualifier 1428 1439	controlados
A11	Assertion T68 Negated
T69	Neg_cue 1386 1388	no
T70	Quantifier_or_Qualifier 1389 1399	controlada
A12	Assertion T70 Negated
T71	Neg_cue 735 737	NO
T74	CONC 738 754	contraindicación
A13	Assertion T74 Negated
#63	AnnotatorNotes T74	C0522473; Contraindication; Qualitative Concept
T76	Observation 1637 1655	cumplir el estudio
A14	Assertion T76 Negated
R1	Negation Arg1:T82 Arg2:T76	
R2	Negation Arg1:T82 Arg2:T48	
R3	Experiences Arg1:T60 Arg2:T3	
R4	Experiences Arg1:T60 Arg2:T4	
R5	Combined_with Arg1:T7 Arg2:T25	
R6	Combined_with Arg1:T7 Arg2:T8	
R7	Combined_with Arg1:T7 Arg2:T26	
R8	Combined_with Arg1:T26 Arg2:T27	
R9	Causes Arg1:T86 Arg2:T9	
R10	Causes Arg1:T86 Arg2:T10	
R11	Experiences Arg1:T61 Arg2:T7	
R12	Experiences Arg1:T61 Arg2:T9	
R13	Experiences Arg1:T61 Arg2:T10	
R14	Causes Arg1:T85 Arg2:T13	
R15	Causes Arg1:T85 Arg2:T12	
T77	Result_or_Value 677 682	0 o 1
T78	CONC 672 676	ECOG
#64	AnnotatorNotes T78	C1520224;ECOG performance status; Intellectual Product
R16	Has_Result_or_Value Arg1:T78 Arg2:T77	
R17	Used_for Arg1:T78 Arg2:T66	
T81	CONC 708 730	inicio de los síntomas
R18	After Arg1:T81 Arg2:T65	
R19	Negation Arg1:T71 Arg2:T74	
T87	Observation 780 782	QT
#65	AnnotatorNotes T87	C0577807; QT interval duration; Finding
T88	Duration 783 788	< 0.4
R20	Overlap Arg1:T19 Arg2:T87	
R21	Has_Duration_or_Interval Arg1:T87 Arg2:T88	
R22	Location_of Arg1:T20 Arg2:T63	
R23	Location_of Arg1:T21 Arg2:T63	
T89	Quantifier_or_Qualifier 834 842	adecuada
#66	AnnotatorNotes T89	C0205411; Adequate; Qualitative Concept 
R24	Has_Quantifier_or_Qualifier Arg1:T63 Arg2:T89	
T90	Result_or_Value 939 952	> 1.5 x 109/L
R25	Has_Result_or_Value Arg1:T50 Arg2:T90	
T91	Result_or_Value 984 997	> 100 x 109/L
R26	Has_Result_or_Value Arg1:T55 Arg2:T91	
T92	Result_or_Value 1004 1013	> 10 g/dL
R27	Has_Result_or_Value Arg1:T51 Arg2:T92	
T93	Result_or_Value 1020 1031	< 1.5 mg/dL
R28	Has_Result_or_Value Arg1:T52 Arg2:T93	
T94	Result_or_Value 1047 1057	> 50mL/min
R29	Has_Result_or_Value Arg1:T47 Arg2:T94	
T95	Result_or_Value 1073 1080	< 3 LSN
R30	Has_Result_or_Value Arg1:T53 Arg2:T95	
T96	Result_or_Value 1092 1107	≤ 2,5 veces LSN
R31	Has_Result_or_Value Arg1:T29 Arg2:T96	
R32	Has_Result_or_Value Arg1:T54 Arg2:T96	
R33	Negation Arg1:T72 Arg2:T28	
R34	Negation Arg1:T73 Arg2:T30	
R35	Used_for Arg1:T32 Arg2:T31	
T97	Quantifier_or_Qualifier 1270 1275	grave
#67	AnnotatorNotes T97	C1547227; Severe - Severity of Illness Code; Intellectual Product
R36	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T97	
R37	Overlap Arg1:T35 Arg2:T75	
R38	Location_of Arg1:T56 Arg2:T38	
R39	Negation Arg1:T69 Arg2:T70	
R40	Negation Arg1:T67 Arg2:T68	
R41	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T68	
R42	Has_Quantifier_or_Qualifier Arg1:T39 Arg2:T70	
T98	Observation 1369 1378	inestable
#68	AnnotatorNotes T98	C0443343; Unstable status; Finding
R43	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T98	
T99	Quantifier_or_Qualifier 1455 1461	graves
#69	AnnotatorNotes T99	C1547227; Severe - Severity of Illness Code; Intellectual Product
R44	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T99	
T100	Quantifier_or_Qualifier 1462 1469	activas
#70	AnnotatorNotes T100	C0679217; Active State; Idea or Concept
R45	Has_Quantifier_or_Qualifier Arg1:T41 Arg2:T100	
T101	Quantifier_or_Qualifier 1540 1546	activo
#71	AnnotatorNotes T101	C0679217; Active State; Idea or Concept
R46	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T101	
T102	Quantifier_or_Qualifier 1492 1499	activas
#72	AnnotatorNotes T102	C0679217; Active State; Idea or Concept
R47	Has_Quantifier_or_Qualifier Arg1:T42 Arg2:T102	
R48	Negation Arg1:T79 Arg2:T45	
R49	Has_Route_or_Mode Arg1:T45 Arg2:T80	
R50	Overlap Arg1:T58 Arg2:T83	
T103	Quantifier_or_Qualifier 1754 1777	clínicamente relevantes
R51	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T103	
R52	Experiences Arg1:T84 Arg2:T64	
T104	Quantifier_or_Qualifier 352 358	precoz
#73	AnnotatorNotes T104	C1279930; Precocious; Temporal Concept
R53	Has_Quantifier_or_Qualifier Arg1:T26 Arg2:T104	
R54	Has_Quantifier_or_Qualifier Arg1:T27 Arg2:T104	
R55	Negation Arg1:T79 Arg2:T80	
#74	AnnotatorNotes T103	C5209294; Clinical relevance; Intellectual Product
#75	AnnotatorNotes T33	C0243087; concomitant disease; Pathologic Function (?)
#76	AnnotatorNotes T50	C0948762; Absolute neutrophil count; Laboratory Procedure
#77	AnnotatorNotes T55	C0032181; Platelet count (procedure); Laboratory Procedure (?)
A15	Experiencer T60 Patient
A16	Experiencer T61 Patient
A17	Experiencer T84 Patient
